Compare Illumina, Inc. (ILMN) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Oracle Corporation — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while Oracle Corporation trades at $122.31 (market cap $349.63B). The key difference: Oracle Corporation is far larger — about 12.5× Illumina, Inc.'s market cap, and Oracle Corporation pays a 1.65% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | ORCL | |
|---|---|---|
Market Cap | $27.94B | $349.63B |
Sector | Health | Technology |
52-Week High | $194.33 | $328.33 |
52-Week Low | $91.00 | $121.37 |
Enterprise Value | $29.33B | $478.88B |
Dividend Yield | — | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Oracle (ORCL) trades at $121.37, down 4.04% today amid AI infrastructure spending concerns. The stock shows strong fundamental performance with consistent earnings beats (Q1 2026 EPS of $2.11 vs. $1.96 expected) and robust profitability metrics (65.82% gross margin, 58.56% ROE). Technical indicators are mixed with bearish moving averages but bullish oscillators, while analyst consensus remains strongly positive with a $253.30 price target representing significant upside potential.
Oracle presents a compelling investment case with strong AI positioning and consistent execution, though near-term volatility may persist due to high capital expenditure requirements. The company's transformation into an AI infrastructure leader and improving debt profile (debt-to-asset ratio declining to 55.15% in 2025) support long-term growth, but investors should monitor execution risks and competitive pressures in the evolving cloud market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
